Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up
Pharmaron, the secondly largest CRO based in China, launched book building today to raise up to USD 588 million to list in Hong Kong. In our...
663 Views
Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation
Pharmaron, a leading contract research company, is looking to list in Hong Kong by raising up to USD 600 million. In our previous note, we have...
722 Views
Pharmaron Beijing IPO: Solid 9M19, but Is It Good Enough?
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
518 Views
Pharmaron Beijing IPO Initiation: Clinically Sound
Pharmaron Beijing Co., Ltd. (A) (300759 CH) is a global contract research organisation (CRO) and is one of the top three drug discovery service...
633 Views
Pharmaron (康龙化成) A+H Listing: A Leading Drug Discovery Company
Pharmaron, a leading contract research company, is looking to list on the H-Share market by raising up to USD 600 million. In this insight, we will...
967 Views